New England Capital Financial Advisors’s Edwards Lifesciences EW Stock Holding History

New England Capital Financial Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.8K	Hold	528	–	–	0.01%	134
2026 Q1	$42.3K	Hold	528	–	–	0.01%	141
2025 Q4	$45K	Hold	528	–	–	0.02%	136
2025 Q3	$41.1K	Hold	528	–	–	0.02%	138
2025 Q2	$41.3K	Hold	528	–	–	0.02%	128
2025 Q1	$38.3K	Hold	528	–	–	0.02%	129
2024 Q4	$39.1K	Hold	528	–	–	0.02%	127
2024 Q3	$34.8K	Hold	528	–	–	0.02%	140
2024 Q2	$48.8K	Hold	528	–	–	0.03%	109
2024 Q1	$50.5K	Hold	528	–	–	0.03%	111
2023 Q4	$40.3K	Hold	528	–	–	0.02%	126
2023 Q3	$36.6K	Hold	528	–	–	0.03%	124
2023 Q2	$49.8K	Hold	528	–	–	0.03%	112
2023 Q1	$43.7K	Hold	528	–	–	0.03%	128
2022 Q4	$41.9K	Buy	+528	New	+$40.7K	0.03%	135

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

New England Capital Financial Advisors's EW Position: Q2 2026 in Review

New England Capital Financial Advisors held its Edwards Lifesciences (EW) position steady in Q2 2026 at 528 shares worth $47.8K. The position accounts for 0.01% of the portfolio, ranked #134.

New England Capital Financial Advisors first reported a position in EW in Q4 2022 and has held it in 15 quarters since. The position peaked at $50.5K in Q1 2024. 928 funds tracked by Wall St. Rank hold EW as of Q2 2026.

New England Capital Financial Advisors held 528 shares of Edwards Lifesciences worth $47.8K as of Q2 2026.
New England Capital Financial Advisors left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up 0.01% of New England Capital Financial Advisors's portfolio in Q2 2026, its #134 holding.
New England Capital Financial Advisors first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 15 quarters since.
New England Capital Financial Advisors's Edwards Lifesciences position peaked at $50.5K in Q1 2024.
928 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on New England Capital Financial Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.